您现在的位置: 首页   -  产品中心   -  免疫学   -   抗体
LY75/CD205 His Tag Protein, Human

LY75/CD205 His Tag Protein, Human

货号: UA011116
价格: 1280
规格: 25μg
介绍: -
其他: -
产品规格
  • 物种

    Human
  • 分子别名

    LY75, CD205, DEC-205, CLEC13B, Lymphocyte antigen 75, gp200-MR6
  • Accession

    O60449-1
  • 表达序列

    Ser28-Asp1666 with His Tag at C-Terminus

  • 表达宿主

    HEK293
  • 分子量

    170-200kDa (Reducing)

  • 纯度

    >95% by SDS-PAGE
  • 标记

    Unconjugated
  • 标签

    His Tag
  • 性状

    Lyophilized Powder
  • 缓冲体系

    PBS, PH7.4, 5% trehalose
  • 溶解方法

    Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

  • 储存条件

    · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. 
    · 3 months, -20 to -80℃ under sterile conditions after reconstitution.
    · 1 week, 2 to 8℃ under sterile conditions after reconstitution.  
    · Please avoid repeated freeze-thaw cycles.

  • 文献引用

    Yun Z, Liu Z, Shen Y, Sun Z, Zhao H, Du X, Lv L, Zhang Y, Hou L. Genetic analysis from multiple cohorts implies causality between 2200 druggable genes, telomere length, and leukemia. Comput Biol Med. 2024 Oct;181:109064.

  • 稀释度

背景介绍
  • Lymphocyte antigen 75 (Ly75), also known as CD205, CLEC13B, GP200-MR6, and DEC-205, is a type I transmembrane protein predominantly expressed on dendritic cells and thymic epithelial cells. Ly75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has demonstrated strong preclinical anti-tumor activity in lymphoma models.
    Upon verification as a monotherapy in vivo, the antibody-drug conjugate (ADC) has been found to have a synergistic effect when combined with the BCL2 inhibitor Venetoclax and the anti-CD20 monoclonal antibody rituximab.

  • 电泳JSON

    • 1μg (R: reducing condition, N: non-reducing condition).